HIV Archives

News and Trends 8 Sep 2021

As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues

Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances. HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence […]

September 8, 2021 - 5 minutesmins - By Helen Albert

gene therapy blood disorder hemophilia b

News and Trends 4 Feb 2021

HIV Drug Approvals Lift Hopes Amid Missed UN Targets

The recent approvals of long-acting HIV injections promise to lighten the load of HIV sufferers around the world. However, a vital UN deadline for improving global HIV healthcare has slipped away. At the end of January, ViiV Healthcare’s Cabenuva became the first long-acting HIV treatment to be approved by the FDA. This decision, in addition […]

February 4, 2021 - 6 minutesmins - By Anita Chakraverty

News and Trends 23 Mar 2020

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […]

March 23, 2020 - 2 minutesmins - By Jonathan Smith

colorectal cancer mologen cancer immunotherapy

News and Trends 6 Dec 2019

Update: Cancer Immunotherapy Biotech Files for Insolvency

Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […]

December 6, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […]

November 22, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Aug 2019

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jul 2019

HIV Drug Suppresses Virus for Almost Two Years When Other Treatments Fail

A first-in-class HIV treatment developed by the UK company ViiV Healthcare has suppressed the virus in people who have become resistant to other antiretroviral drugs, providing protection for at least 96 weeks. The phase III trial tested ViiV Healthcare’s first-in-class drug fostemsavir in 272 HIV-infected people who had failed to respond to approved antiretroviral drugs. […]

July 23, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jul 2019

EU Approves Two-Drug Pill as First-Line Treatment for HIV

The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […]

July 3, 2019 - 2 minutesmins - By Jonathan Smith

Startup Scout 14 Jun 2019

This Biotech Reduces Drug Side Effects Using Silica Gel Implants

DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over time, causing fewer side effects and helping patients stick to their treatment regimen. Mission: To develop silica gels that slowly release drugs over time to treat conditions including HIV, hepatitis B, retinal disease and cancer. One big problem in chronic […]

June 14, 2019 - 3 minutesmins - By Jonathan Smith

Interview 12 Jun 2019

How Vaccines Could One Day Beat HIV

Vaccines are humanity’s biggest achievement against infectious diseases. But could they defeat HIV, a particularly crafty virus? José Luis Cabero, CEO of Spanish biotech AELIX Therapeutics shared his experience developing an HIV vaccine at Labiotech Refresh in Barcelona. The concept of a vaccine is simple — priming the immune system against a pathogen so that […]

June 12, 2019 - 5 minutesmins - By Jonathan Smith

News and Trends 3 Jun 2019

‘CRISPR Babies’ Might Be at Risk of Dying Younger

Update (01/10/2019): The scientists behind the study have declared that the results were based on erroneous data, meaning the mutation they studied has a weaker effect on mortality than initially reported. A new study highlights the issues that can result from modifying human DNA without sufficient understanding of how it can impact our health. Last […]

June 3, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

GSK ViiV Healthcare Double HIV Treatment

News and Trends 4 Apr 2019

Update: Two-Drug HIV Treatment Effective for up to Three Years

Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […]

April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us